论文部分内容阅读
急性冠状动脉综合征(ACS)是一组由急性心肌缺血引起的临床综合征,是心脏性死亡的主要原因之一。ACS的主要发病机制是斑块破裂伴发血栓形成,抗凝与抗血小板治疗成为其主要的药物治疗手段。目前ACS的抗凝与抗血小板治疗标准还存在不少局限,作用有限而出血并发症发生比例较高。现在有关新标准与新药物的大量研究正在进行。现综合近期公布的研究结果,对一些抗凝与抗血小板药物的理化特性和临床研究结果予以综述。
Acute coronary syndrome (ACS) is a group of clinical syndromes caused by acute myocardial ischemia and is one of the major causes of cardiac death. The main pathogenesis of ACS is plaque rupture associated with thrombosis, anticoagulant and antiplatelet therapy has become its main drug treatment. Current ACS anticoagulant and antiplatelet standards there are many limitations, limited role and a higher proportion of bleeding complications. Numerous studies are now underway on new standards and new drugs. Based on the recently published research results, the physico-chemical properties and clinical findings of some anticoagulant and anti-platelet drugs are summarized.